Ginkgo biloba extract and alzheimer’s disease: Is the neuroprotection explained merely by the antioxidant action?

Oxidative Stress and Age-Related Neurodegeneration

Volumn , Issue , 2005, Pages 43-58

  Christen, Yves ^a  

^a IPSEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85057702650     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (92)

1. Christen Y. From clinical observations to molecular biology: Ginkgo biloba extract EGb 761, a success for reverse pharmacology. Curr Top Nutraceut Res, 2003; 1:59-72.
2. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset. Am. J. Public Health, 1998; 88:1337-1342.
3. Sloane PD, Zimmerman S, Suchindran C, Reed P, Wang L, Boustani M, Sudha S. The public health impact of Alzheimer’s disease, 2000-2050: potential implication of treatment advances. Annu Rev Public Health, 2000; 23:213-231.
4. AD 2004. Collaborative Group, Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomized double-blind trial. Lancet, 1975; 363:2105-2115.
5. Schneider LS. AD2000: donepezil in Alzheimer’s disease. Lancet, 2004; 363:2100-2101.
6. Citron M. Strategies for disease modification in Alzheimer’s disease. Nature Rev Neurosci, 2004; 5:677-685.
7. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, David KL, Farlow MR, Jin S, Thomas RS, Thal LJ. Alzheimer’s Disease Cooperative Study. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA, 2003; 289:2819-2826.
8. Renes SA, Block GA, Morris JC, Liu G, Nessly ML, Lines CR, Norman BA, Baranak CC. Rofecoxib. No effect on Alzheimer’s disease in a 1-year, randomized, blinded, controlled study. Neurology, 2004; 62:66-71.
9. Espeland MA, Rapp SR, Shumaker SA, Brunner R, Manson JE, Sherwin BB, Hsia J, Margolis KL, Hogan PE, Wallace R, Dailey M, Freeman R, Hays J for the Women’s Health Initiative Memory Study Investigators. Conjugated equine estrogens and global cognitive function in postmenopausal women. JAMA, 2004; 291:2959-2968.
10. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones BN 3rd, Assaf AR, Jackson RD, Kotchen JM, Wassertheil-Smoller S, Wactawski-Wende J. WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA, 2003; 289:2651-2662.
11. Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, Fillit H, Stefanick ML, Hendrix SL, Lewis CE, Masaki K, Coker LH, for the Women’s Health Initiative Memory Study Investigators. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women. JAMA, 2004; 291:2947-2958.
12. Engelhart MJ, Geerlings MI, Ruitenberg A, van Swieten JC, Hofman A, Witteman JC, Breteler MM. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA, 2002; 287:3223-3229.
13. Commenges D, Scotet V, Renaud S, Jacqmin-Dadda H, Berberger-Gateau P, Dartigues JF. Intake of flavonoids and risk of dementia. Eur J Epidemiol, 2000; 16:357-363.
14. Morris MC, Evans DA, Bienas JL, Tangney CC, Bennett DA, Agarwal N, Wilson RS, Scher PA. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA, 2002; 287:3230-3237.
15. Orgogozo JM, Dartigues JF, Lafont S, Letteneur L, Commenges D, Salamon R, Renaud S, Breteler MB. Wine consumption and dementia in the elderly: a prospective community study in the Bordeaux area. Rev Neurol (Paris) 1997; 153:185-192.
16. Zandi PP, Anthony JC, Kachaturian AS, Stone SV, Gustafson D, Tschantz JT, Norton MC, Welsh-Bohmer KA, Breitner JC. Cache County Study Group, Reduced risk of Alzheimer disease in users of antioxidant vitamins supplements: The Cache County Study. Arch Neurol, 2004; 61:82-88.
17. Lansbury PT Jr. Back to the future: the ‘old-fashioned’ way to new medicatrions for neurodegeneration. Nature Med, 2004; 10(Suppl.):S51-S57.
18. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimr’s disease: progress and problems on the road to therapeutics. Science, 2002; 297:353-356.
19. Belgery M, Morley JE. A step back in time: is there a place for older drugs in the treatment of dementia? J Gerontol Med Sci, 2004; 59A:1025-1028.
20. Kressmann S, Müller WE, Blume HH, Pharmaceutical quality of different Ginkgo biloba brands. J Pharm Pharmacol, 2002; 54:661-669.
21. McCutcheon AR. An exploration of current issues in botanical quality: A discussion paper. Natural Health products Directorate, Health Canada, Dec. 2002.
22. Mantle D, Wilkins RM, Gok MA. Comparison of antioxidant activity in commercial Ginkgo biloba preparations. J Altern Complement Med, 2003; 5:625-629.
23. Le Bars PL, Katz MM, Berman N, Itil T, Freedman AM, Schalzberg AF, A placebo-controlled double-blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA, 1997; 278:1327-1332.
24. Oken BS, Storzbach DM, Kaye JA. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol, 1998; 55:1409-1415.
25. Kanowski S, Hoerr R. Ginkgo biloba extract EGb 761 in dementia: intent-to-treat analyses of a 24-week, multi-center, double-blind, placebo-controlled, randomized trial. Pharmacopsychology, 2003; 36:297-303.
26. van Dongen M, van Rossum E, Kessels A, Sielhorst H, Knipschild P. The efficacy of ginkgo elderly people with dementia and age-associated memory impairment: new results of a randomized clinical trial. J Am Geriat Soc, 2000; 48:1183-1194.
27. van Dongen M, van Rossum E, Kessels A, Sielhorst H, Knipschild P. Ginkgo for elderly people with dementia and age-associated memory impairment: a randomized clinical trial. J Clin Epidemiol, 2003; 56:367-376.
28. Birks J, Grimley EV, Van Dongen M. Ginkgo biloba for cognitive impairment and Dementia. Cochrane Datab Syst Rev, 2002; 4:CD003120.
29. Birks JS, Harvey R. Donepezil for dementia due to Alzheimer’s disease. Cochrane Datab Syst Rev, 2003; 3:CD001190.
30. Schneider LS, DeKosky ST, Farlow MR, Tariot PN, Hoerr R. A randomized doubleblind, placebo-controlled trial of two doses of Ginkgo biloba extract in Alzheimer’s disease. Meeting of the International College of Geriatry and Neuropharmacology, Basel, October 16th, 2004, Abstract.
31. Hoerr R. Behavioural and psychological symptoms of dementia (BPSD): effects of EGb 761. Pharmacopsychiat, 2003; 36(Suppl. 1):S56-S61.
32. Andrieu S, Gillette S, Amouyal K, Nourhashemi F, Reynish W, Ousset PJ, Albarède JL, Vellas B, Grandjean H. Association of Alzheimer’s disease onset with Ginkgo biloba and other symptomatic cognitive treatments in a population of women aged 75 years and older from the EPIDOS Study. J Gerontol A Biol Sci Med Sci, 2003; 58:372-377.
33. Palmer K, Bäckman L, Winblad B, Fratiglioni L. Detection of Alzheimer’s disease and dementia in the preclinical phase: population based cohort study. Br Med J, 2004; 326:245-249.
34. Polich J, Gloria R. Cognitive effects of a Ginkgo biloba/vinpocetine compound in normal adults: systematic assessment of perception, attention and memory. Hum Psychophamacol Clin Exp, 2001; 16:409-416.
35. Israel L, Dell’Accio E, Martin G, Hugonot R. Extrait de Ginkgo biloba et exercices d’entraînement de la mémoire. Evaluation comparative chez des personnes âgées ambulatoires. Psychol Méd, 1987; 19:1431-1439.
36. Rigney U, Kimber S, Hindmarch I. The effects of acute doses of standardized Ginkgo biloba extract on memory and psychomotor performance in volunteers. Phytother Res, 1999; 13:408-415.
37. Stough C, Clarke J, Lloyd J, Nathan PJ. Neuropsychological changes after 30-day Ginkgo biloba administration in healthy participants. Int J Neuropsychopharmacol, 2001; 4:131-134.
38. Taillandier J, Ammar A, Rabourdin JP, Ribeyre JP, Pichon J, NiddamS, Pierart H. Traitement des troubles du vieillissement cérébral par l’extrait de Ginkgo biloba; Etude longitudinale multicentrique à double insu face au placebo. Presse Méd, 1986; 15:1583-1587.
39. Wesnes K, Simmons D, Rook M, Simpson P. A double-blind placebo-controlled trial of Tanakan in the treatment of idiopathic cognitive impairment in the elderly. Hum Psychopharmacol, 1987; 2:159.
40. Kenney C, Norman M, Jacobson M, Lampinen S, Nguyen DP, Corey-Bloom J. 37. A double-blind, placebo-controlled, modified crossover pilot study of the effects of Ginkgo biloba on cognitive and functional abilities in multiple sclerosis. Neurology, 2002; 58(Suppl. 3):A458-A459.
41. Kennedy DO, Scholey AB, Wesnes KA. The dose-dependent cognitive effects of acute administration of Ginkgo biloba to healthy young volunteers. Psychopharmacol, 2000; 151:416-423.
42. Mix JA, Crews Jr WD. An examination of the effocacy of Ginkgo biloba extract EGb 761 on the neuropsychologic functioning of cognitively intact older adults. J Altern Complement Med, 2000; 6:219-229.
43. Mix JA, Crews Jr WD. A double-blind, placebo-controlled, randomized trial of Ginkgo biloba extract EGb 761 in a sample of cognitively intact older adults: neuropsychological findings. Human Psychopharmacol, 2002; 17:267-277.
44. Scholey AB, Kennedy DO. Acute, dose-dependent cognitive effects of Ginkgo biloba, Pana ginseng, and their combination in healthy young volunteers: differential interactions with cognitive demand. Hum Psychopharmacol Clin Exp, 2002; 17: 35-44.
45. Warot D, Lacomblez L, Danjour E, Weiller E, Payan C, Puech AJ. Comparaison des effets d’extraits de Ginkgo biloba sur les performances psychomotrices et la mémoire chez le sujet sain. Thérapie 1991; 46:33-36.
46. Solomon PR, Adams F, Silver A, Zimmer J, De Veaux R. Ginkgo for memory enhancement. A randomized controlled trial. JAMA, 2002; 288:835-840.
47. Droy-Lefaix MT. Effect of the antioxidant action of Ginkgo biloba extract (EGb 761) on aging and oxidative stress. Age, 20;141-149, 1997.
48. Packer L, Saliou C, Droy-Lefaix MT, Christen Y. Ginkgo biloba extract EGb 761: antioxidant activity, and regulation of nitric oxide synthase. In: Rice-Evans CA, Packer L, eds. Flavonoids in Health and Disease. New York: Marcel Dekker, 1998:303-341.
49. Pierre S, Jamme I, Robert K, Gerbi A, Duran MJ, Sennoune S, Droy-Lefaix MT, Nouvelot A, Maixent JM. Gingko biloba extract (EGb 761) protects Na, K-ATPase isoenzymes during cerebral ischemia. Cell Mol Biol, 2002; 48:671-679.
50. Pietri S, Séguin JR, d’Arbigny P, Drieu K, Culcasi M. Gingko biloba extract (EGb 761) pretreatment limits free radical-induced oxidative stress in patients undergoing coronary bypass surgery. Cardiovasc Drugs Therapy, 1997; 11:121-131.
51. Christen Y. Oxidative stress and Alzheimer disease. Am J Clin Nutr, 2000; 71(Suppl.):621S-629S.
52. Pratico D, Clark CM, Lium F, Lee VY, Trojanowski JQ. Increase of brain oxidative stress in mild cognitive impairment. Arch Neurol, 2002; 59:972-976.
53. 2α-VI in Alzheimer’s disease: correlation of a non-invasive index of lipid peroxidation with disease severity. Ann Neurol, 2000; 48:809-812.
54. Huang X, Atwood CS, Hartshorn MA, Multhaup G, Goldstein LE, Scarpa RC, Cuajungco MP, Gray DN, Lim J, Moir RD, Tanzi RE, Bush AI. The Aß peptide of Alzheimer’s disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry, 1999; 38:7609-7616.
55. Pratico D, Uryu K, Leight S, Trojanowski JQ, Lee VM. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci, 2001; 21:4183-4187.
56. Behl C, Moosmann B. Antioxidant neuroprotection in Alzheimer’s disease as preventive and therapeutic approach. Free Radic Biol Med, 2002; 33:82-191.
57. Smith VJ, Luo Y. Elevation of oxidative free radicals in Alzheimer’s disease models can be attenuated by Gingko biloba extract EGb 761. J Alzheimer, 2003; 5:287-300.
58. Ramassamy C, Averill D, Beffert U, Bastianetto S, Theroux L, Lussier-Cacan S, Cohn JS, Christen Y, Davignon J, Quirion R, Poirier J. Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer’s disease is related to the apolipoprotein E genotype. Free Rad Biol Med, 1999; 27:544-553.
59. Ramassamy C, Averill D, Beffert U, Theroux L, Lussier-Cassan S, Cohn JS, Christen Y, Schoofs A, Davignon J, Quirion R, Poirier J. Oxidative insults are associated with apolipoprotein E genotype in Alzheimer’s disease brain. Neurobiol Disease, 2000; 7:23-37.
60. Backsai BJ, Klunk WE, Hickey GA, Skoch J, Kajdasz ST, McLellan ME, Frosch MP, Debnath M, Holt D, Wang Y, Huang G-f, Mathis CA, Hyman BT. In vivo imaging of Alzheimer pathology in transgenic mice using multiphoton microscopy. In: Hyman BT, Demonet JF, Christen Y, eds. The living brain and Alzheimer’s disease. Heidelberg: Springer Verlag, 2004:33-45.
61. Bastianetto S, Ramassamy C, Doré S, Christen Y, Poirier J, Quirion R. The Ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by jö-amyloid. Eur J Neurosci, 2000; 12:882-1890.
62. Yao ZX, Drieu K, Papadopoulos V. The Ginkgo biloba extract EGb 761 rescues the PC 12 neuronal cells from β-amyloid-induced cell death by inhibiting the formation of ö-amyloid-derived diffusible neurotoxic ligands. Brain Res, 2001; 889:181-190.
63. Luo Y, Smith JV, Paramasivan V, Burdick A, Curry KJ, Bufford JP, Khan I, Netzer WJ, Xu H, Butko P. Inhibition of amyloid- β aggregation and caspase-3 activation by the Ginkgo biloba extract EGb 761. Proc Natl Acad Sci USA, 2002; 99:2197-2202.
64. Ahlemeyer B, Mowes A, Krieglstein J. Inhibition of serum deprivation and stau-rosporine-induced neuronal apoptosis by Ginkgo biloba extracts and some of its constituents. Eur J Pharmacol, 1999; 367:423-430.
65. Bastianetto S, Zheng WH, Quirion R. The Ginkgo biloba extract (EGb 761) protects and rescues hippocampal cells against nitric oxide-induced toxicity: involvement of its flavonoid constituents. J Neurochem, 2000; 74:2268-2277.
66. Colciaghi F, Borroni B, Zimmermann M, Belkner A, Longhi C, Padovani A, Cattabeni F, Christen Y, Di Luca M. Amyloid precursor protein metabolism is regulated toward alpha-secretase pathway by Ginkgo biloba extracts. Neurobiol Disease, 2004; 16:454-460.
67. Yao ZX, Han Z, Drieu K, Papadopoulos V. Ginkgo biloba extract (EGb 761) inhibits beta-amyloid production by lowering free cholesterol levels. J Nutr Biochem, 2004; 15:749-756.
68. Wu Y, Wu Z, Gutierrez-Zepeda A, Christen Y, Link CD, Luo Y. Modulation of amyloid beta oligomerization and toxicity by Ginkgo biloba extract EGb761 in transgenics Caenorhabditis elegans. Submitted.
69. Mizuno M, Packer L. Ginkgo biloba extract EGb 761 is a suppressor of AP-1 transcription factor stimulated by PMA. Biochem Molec Biol Int, 1996; 39:395-401.
70. Amri H, Ogwuegbu SO, Boujrad N, Drieu K, Papadopoulos V. In vivo regulation of the peripheral-type benzodiazepine receptor and glucocorticoid synthesis by the Ginkgo biloba extract EGb 761 and isolated ginkgolides. Endocrinology, 1996; 137:5707-5718.
71. Amri H, Drieu K, Papadopoulos V. Transcriptional suppression of the adrenal cortical peripheral-type benzodiazepine receptor gene and inhibition of steroid synthesis by ginkgolide B. Biochem Pharmacol, 2003; 65:717-729.
72. Chandrasekaran K, Liu IL, Hätanpää K, Drieu K, Rapoport SI. Stimulation of mitochondrial gene expression by bilobalide, a component of Ginkgo biloba extract, EGb 761. In: Packer L, Christen Y, eds. Ginkgo biloba Extract (EGb 761) Study: Lessons from Cell Biology. Paris: Elsevier, 1998:121-128.
73. Chen JX, Zeng H, Chen X, Su CY, Lai CC. Induction of the heme oxygenase-1 by Gingko biloba extract but not its terpenoids partially mediated its protective effect against lysophosphatidylcholine-induced damage Pharmacol Res, 2001; 43:63-69.
74. Zhuang H, Pin S, Christen Y, Dore S. Induction of heme oxygenase 1 by Ginkgo biloba in neuronal cultures and potential implications in ischemia. Cell Mol Biol, 2002; 48:647-653.
75. Gohil K, Maguire JJ, Packer L. Ginkgo biloba extract, EGb 761, activates antioxidant response and genes for intracellular transport: an in vitro study with GeneChips and a human cancer cell line. In: Christen Y, ed. Ginkgo biloba Extract (EGb 761) as a neuroprotective agent: from basic studies to clinical trials. Marseille: Solal, 2001:13-31.
76. Soulié C, Nicolle A, Christen Y, Ceballos-Picot I. The Ginkgo biloba extract EGb 761 increases viability of hNT human neurons in culture and affects the expression of genes implicated in the stress response. Cell Mol Biol, 2002; 48:641-646.
77. Tendi EA, Bosetti F, DasGupta SF, Giuffrida Stella AM, Drieu, Rapoport S. Ginkgo biloba extracts EGb 761 and bilobalide increase NADH dehydrogenase mRNA level and mitochondrial respiratory control ratio in PC12 cells. Neurochem Res, 2002; 27:319-323.
78. DeFeudis FV. Effects of Ginkgo biloba Extract (EGb 761) on gene expression: possible relevance to neurological disorders and age-associated cognitive impairment. Drug Dev Res, 2002; 57; 214-215.
79. Gohil K, Roy RK, Farzin S, Maguire JJ, Packer L. mRNA expression profile of a human cancer cell line in response to Ginkgo biloba extract: induction of antioxidant response and the Golgi system. Free Rad Res, 2000; 33:831-849.
80. Papadopoulos V, Kapsis A, Li H, Amri H, Hardwick M, Culty M, Kasprzyk PG, Carlson M, Moreau JP, Drieu K. Drug-induced inhibition of the peripheral-type benzodiazepine receptor expression and cell proliferation in human breast cancer cells. Anticancer Res, 2000; 20:2835-2847.
81. Watanabe CMH, Wolffram S, Ader P, Rimbach G, Packer L, Maguire JJ, Schultz PG, Gohil K. The in vivo neuromodulatory effects of the herbal medicine ginkgo biloba. Proc Natl Acad Sci USA, 2001; 98:6577-6580.
82. Clark WM, Rinker LG, Lessov NS, Lowery SL, Cipolla MJ. Efficacy of antioxidant therapies in transient focal ischemia in mice. Stroke 2001; 32:1000-1004.
83. Spinnewyn B. Ginkgo biloba Extract (EGb 761) protects against delayed neuronal deth in gerbils. In: Costentin J, Christen Y, Lacour M, eds. Effects of Gingko biloba extract EGb 761 on the central nervous system. Paris: Elsevier, 1992:113-118.
84. Lee EJ, Chen HY, Wu TS, Chen TY, Ayoub IA, Maynard KI. Acute administration of Ginkgo biloba extract (EGb 761) affords neuroprotection against permanent and transient focal cerebral ischemia in Sprague-Dawley rats. J Neurosci Res, 2002; 68:636-645.
85. Ferrante RJ, Klein AM, Dedeoglu A, Beal MF. Therapeutic efficacy of EGb 761 (Ginkgo biloba Extract) in a transgenic mouse model of amyotrophic lateral sclerosis. J Mol Neurosci, 2001; 17:89-96.
86. Ramassamy C, Clostre F, Christen Y, Costentin J. In vivo Ginkgo biloba extract (EGb 761) protects against neurotoxic effects induced by MPTP: investigations into its mechanism(s) of action. In: Christen Y, Costentin J, Lacours M, eds. Effects of Ginkgo biloba Extract (EGb 761) on the Central Nervous System. Paris: Elsevier, 1992:27-36.
87. Rojas P, Garduno B, Rojas C, Vigueras RM, Rojas-Castaneda J, Rios C, Serrano-Garcia N. EGb 761 blocks MPP+-induced lipid peroxidation in mouse copus striatum. Neurochem Res, 2001; 26:1245-1251.
88. He J, Kim BO, Liu Y. Neuroprotective function of Ginkgo bioba extract (EGb 761) in the brain of doxycycline inducible, brain-targeted human immunodeficiency virus type 1 TAT transgenic mice. In: Ginkgo biloba Extract. From traditional medicine to a medicine of the future; or molecular biology attending a medicine of complexity. Meeting Berlin, October 11-13, 2002. Abstract.
89. Allain H, Raoul P, Lieury A, LeCoz F, Gandon JM, d’Arbigny P. Effect of two doses of Ginkgo biloba extract (EGb 761) on the dual-coding test in elderly subjects. Clin Ther, 1993; 15:549-558.
90. Christen Y. Ginkgo biloba and neurodegenerative disorders. Frontiers Biosci, 2004; 9:3091-3104.
91. Christen Y, Olano-Martin E, Packer L. EGb 761 in the post genomic era; new tools from molecular biology for the study of complex products such as Ginkgo biloba extract. Cell Mol Biol, 2002; 48:593-600.
92. DeFeudis FV. Ginkgo biloba extract (EGb 761). From Chemistry to the Clinic. Wiesbaden: Ullstein Medical, 1998.